BNF:

12.2.1

Status:

Grey

Decision Date:

March 2016

Comments

GREY: for moderate to severe seasonal and perennial allergic rhinitis (aged 12 years or over) following the Allergic Rhinitis in adults and adolescents over 12 years of age (Decision date - May 2019)

Grey Drug Classifications

• 1: Lack of data on effectiveness compared with standard therapy
• 5: Less cost-effective than current standard therapy

search again